Drug intelligence / Profile preview

ASC36

Development stage: Preclinical
Lead developer: Ascletis Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

ASC36 is an investigational, once-monthly, subcutaneously administered **amylin receptor peptide agonist** developed by Ascletis as part of their obesity and metabolic disease portfolio. It is intended to be combined with ASC35 (a GLP-1 receptor/GIP receptor dual peptide agonist) for enhanced clinical effect in obesity treatment. ASC36 is designed for slow-release, long-acting pharmacokinetics, potentially enabling patient-friendly monthly dosing. Mechanistically, it acts as an agonist of the **amylin receptor**, a target known to regulate satiety, gastric emptying, and glycemic control, and is being developed for weight loss and metabolic indications.

Brand names: ASC36ASC-36ASC 36
Other names: ASC36ASC-36ASC 36

Targets

AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on ASC36.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC36.

Explore the full profile